Confirmed Sponsors & Exhibitors

Confirmed Sponsors

ICNMD 2018 would like to thank the following companies for their generous support:



Biogen Alexion






Confirmed Exhibitors

Alexion | Booth#3-4
Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. RNAi therapeutics represent a powerful, clinically-validated approach for the treatment of a wide range of debilitating diseases. (
Audentes Therapeutics | Booth #16
Audentes Therapeutics is a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities. (
AveXis | Booth #17
AveXis is a clinical-stage gene therapy company dedicated to developing novel treatments for patients suffering from rare and life-threatening neurological diseases such as spinal muscular atrophy (SMA).  For more information about AveXis, gene therapy, or SMA, please visit our website. (
Biogen | Booth #10-11
Cadwell | Booth #7
Cadwell has developed American-made, innovative neurodiagnostic and neuromonitoring equipment since 1979. Our Arc EEG, Sierra EMG/EP, Cascade IONM, Easy III PSG and CadLink data management solutions help you manage efficient workflows, quality data, reliable performance and easy reporting. We are dedicated to helping you help others. (
CSL Behring | Booth #12
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ need using the latest technologies to develop and deliver innovative biotherapies that are used to treat serious and rare conditions such as coagulation disorders, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. (
EAN provides a go-to resource for everyone working in the fields of neurology and neuroscience. Our mission is to increase and share neurological excellence in Europe and worldwide. We organise an annual congress to bring members together to share the most exciting latest developments and provide a platform for learning. (
European Neuromuscular Centre (ENMC)
Genea Biocells | Booth #8
Genea Biocells is a neuromuscular disease-focused discovery stage company using proprietary human pluripotent stem cell technologies. We leverage our expertise in human pluripotent stem cell derivation, banking and unique skeletal muscle differentiation for disease modeling, assay development and screening. We provide services and reagents to foster partnerships for drug development. (
IOS Press (Journal of Neuromuscular Diseases)
IOS Press, established in 1987, publishes around 100 international journals and approximately 75 book titles annually, in a broad range of subjects. IOS Press has a strong neurosciences package that includes Journal of Neuromuscular Diseases, along with Journal of Alzheimer’s Disease, Journal of Parkinson’s Disease and Journal of Huntington’s Disease. (
Philips Healthcare | Booth #14
PTC Therapeutics | Booth #1
PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development and commercialisation of novel orally administered drugs that target RNA mechanisms affecting protein production.  It is PTC’s mission to bring new therapies to patients affected by rare and neglected diseases (
Sanofi Genzyme | Booth #15
Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. (
Santhera Pharmaceuticals | Booth #9
Santhera Pharmaceuticals is a Swiss speciality pharmaceutical company committed to developing medicines to meet the needs of patients living with mitochondrial disorders and other rare diseases. Our focus is on developing treatments for neuromuscular and neuro-ophthalmological diseases that currently lack treatment options, and have a severe impact on patients’ lives. (
Sarepta | Booth #18
Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. Sarepta is working to rapidly advance its exon-skipping platform for the development of treatments for Duchenne muscular dystrophy and is proud to support the 15th International Congress on Neuromuscular Disease. (
University of Florida Health Shands Hospital | Table #A
The University of Florida Neuromuscular Division is a group of faculty and staff in the Department of Neurology at UF dedicated to improving the condition of those patients suffering from neuromuscular disorders while conducting a wide array of research projects aimed at better understanding the mysteries behind neuromuscular action and dysfunction. (


ICNMD 2018 Floorplan

(Click image to view in full)

Conference Newsletter


Subscribe to the Newsletter to receive important information about the upcoming Conference.